MIRM250117P45000
- 3.10
- 0.000.00%
Mirum Pharmaceuticals Newsroom
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $74
Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)
Evercore Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $68
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $60
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $50 to $70
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Mirum Pharmaceuticals Analyst Ratings
Promising Outlook for Mirum Pharmaceuticals: Buy Rating Justified by Strong Performance and Strategic Initiatives
Mirum Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
Mirum Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $44
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Mirum Pharmaceuticals Analyst Ratings